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                        Many challenges exist in the management of metastatic breast 
cancer (MBC). As opposed to early disease, for which level 1 evi-
dence exists for the majority of treatment alternatives, there are 
few recognized therapeutic standards for MBC, particularly fol-
lowing initial chemotherapy (  1  ). Randomized controlled trials in 
MBC are usually conducted in the first-line setting and address 
specific questions regarding the efficacy, safety, and tolerability of 
individual drugs. The design of these trials is sometimes at odds 
with the questions clinical oncologists face in daily practice. Several 
international guidelines for adjuvant therapy are widely used (  2    –    4  ), 
but consensus statements regarding the management of MBC are 
lacking (  5  ). Acknowledging the urgent need for these initiatives, 
the European School of Oncology (ESO) joined with the European 
Breast Cancer Conference (EBCC) to create an MBC Task Force 
in 2005. The task force held its first open meeting at the EBCC-5 
in Nice in March 2006. This interactive session addressed many of 
the main issues in MBC, and 12 consensus statements regarding 
MBC management were subsequently published (  1  ). 
  At the EBCC-6 in Berlin in April 2008, the second public ses-
sion on MBC Guidelines was held. During this session, three of the 
most controversial issues outlined in the 12 statements were selected 
for further discussion. Here, we summarize the discussion and the 
related recommendations regarding the optimal use of chemother-
apy in MBC, focusing on the still unresolved issue of whether it is 
better to treat MBC patients sequentially with single cytoxic agents 
or to treat them simultaneously with a combination of drugs. 
  The initial consensus statement regarding this subject (consen-
sus statement 9) from the ESO-MBC Task Force guidelines reads: 
“The choice between sequential use of single cytotoxic drugs and 
combination chemotherapy should be taken after consideration of 
the factors mentioned in [  Table 1  ], with greatest emphasis on the 
need for a rapid and signiﬁ  cant response and on quality of life 
(QoL). For the majority of patients, overall survival (OS) outcomes 
from sequential use of single cytotoxic drugs are equivalent to 
combination chemotherapy. Duration of each regimen and num-
ber of regimens should be tailored to each individual patient” (  1  ).         
  Although the Early Breast Cancer Trialists’ Collaborative 
Group (EBCTCG) overview established the survival beneﬁ  t of 
adjuvant polychemotherapy (  6  ), the role of polychemotherapy in 
MBC remains largely unsettled. Unlike the adjuvant setting, in 
which the goal of therapy is cure, the aim of therapy in the setting 
of MBC is essentially palliation. Stepwise advances in chemother-
apy have produced statistically signiﬁ  cant improvements in sur-
vival (  7  ). Nevertheless, tolerability and QoL are important factors 
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in therapeutic decision making that must be balanced with any 
potential gains in disease response or survival. 
  Objective improvements in OS are difﬁ  cult to demonstrate in 
individual trials (  8  ), leading some authors to question whether OS 
is an appropriate endpoint for clinical trials testing novel therapeu-
tic approaches for metastatic disease (  9  ). Accordingly, many recent 
registration trials were designed to detect improvements in 
progression-free interval and were not adequately powered to 
evaluate the impact of new treatments on OS (  10    –    12  ). Crossover 
to the novel agent following progression in the monotherapy arm 
was not mandated, limiting the application of these studies to the 
clinically important question of the relative beneﬁ  ts of combination 
vs sequential monotherapy. Recent data from single-institution series 
and population-based registries demonstrate that the survival of 
patients with MBC has improved over time, coincident with the 
widespread availability of newer and more effective systemic thera-
pies (  13  ,  14  ). Although these data suggest a possible change in the 
natural history or staging procedures of MBC, they do not provide 
insight regarding the optimal timing, sequence, or combination of 
systemic agents in the treatment of MBC. 
  In particular, few appropriately powered randomized clinical 
trials have addressed the question of the sequential use of single 
cytotoxic agents vs upfront combination chemotherapy for MBC, 
with evaluation of the comparative impact of these palliative strate-
gies on patients’ QoL. In contrast to adjuvant therapy, for which 
trials are designed to include thousands of patients to identify small 
absolute differences in disease-free survival, most studies that 
address MBC involve smaller numbers of participants and are 
underpowered to detect potentially meaningful differences in 
progression-free interval and/or OS between combination and 
sequential approaches. 
  A Cochrane Review (  15  ) of 28 trials with 5707 MBC patients who 
were randomly assigned to either single-agent or combination che-
motherapy found that combination chemotherapy was associated with 
a higher response rate (RR) (odds ratio for tumor response     =     1.28, 
95% conﬁ  dence interval [CI]     =     1.15 to 1.42,   P   < .001), longer time 
to progression (hazard ratio [HR] for disease progression     =     0.78, 
95% CI     =     0.73 to 0.83,   P   < .001), and longer OS (HR for death     =       
0.88, 95% CI     =     0.83 to 0.94,   P   < .001) when compared with single-
agent therapy. More toxicity (nausea and vomiting, leucopenia, and 
alopecia) was also observed with combination therapy. Few studies 
included in the Cochrane analysis formally assessed differences in 
QoL between combination and single-agent therapy. 
  In addition, most trials included in the Cochrane meta-analysis 
did not systematically investigate the combination vs the sequential 
approach. Very few trials included in the overview reported the 
rate of “crossover” to an additional agent following progression in 
the monotherapy arm. Such studies test the value of two agents vs 
a single agent but do not address whether a combination or 
sequential monotherapy strategy should be pursued. 
  It is also important to remember that the terms   sequential   and 
  combination   chemotherapy are often used to encompass a variety of 
different therapeutic approaches. For example, sequential therapy 
may refer to the consecutive administration of several chemo-
therapies, with each successive regimen in  troduced following 
either radiographic and/or symptomatic disease progression. 
Alternatively, it may refer to a planned multicourse sequence of 
chemotherapies without interruption between treatment regimens 
(  16  ). Combination therapy may also involve the pairing of a cyto-
toxic drug with a novel biological therapy, such as a taxane and 
trastuzumab in women with HER2-positive MBC. This ESO-
MBC Task Force publication, however, will focus exclusively on 
the combination of cytotoxic chemotherapies vs sequential single-
agent therapies and will not address the optimal addition of bio-
logical therapies to chemotherapy. 
    Literature Review 
    Anthracycline Alone vs Combination Therapy 
  Anthracyclines are among the most active agents against breast 
cancer. The EBCTCG overview demonstrated that the addition of 
an anthracycline to adjuvant systemic therapy was associated with 
a 16% reduction in relative risk of breast cancer mortality (HR for 
breast cancer mortality     =     0.84;   P   < .001), when compared with 
cyclophosphamide-methotrexate-5-fluorouracil (CMF) (  6  ). In the 
metastatic setting, anthracyclines have been used for the past 
30 years and are widely considered as the standard first-line ther-
apy for MBC. Given their established role, many trials have com-
pared single vs combination strategies using an anthracycline as 
the standard single-agent reference regimen (    Supplementary   
  Tables     1     and     2    , available online). An anthracycline is often com-
bined with cyclophosphamide and 5-fluorouracil (5-FU) because 
of their partial lack of cross-resistance and nonoverlapping toxicity 
profiles. The addition of 5-FU and cyclophosphamide to epirubi-
cin (FEC) was associated with an increase in RR: RRs for epirubi-
cin (75 mg/m  2  ) alone, FEC50 (epirubicin at 50 mg/m  2  ), and 
FEC75 (epirubicin at 75 mg/m  2  ) were 30.6%, 44.6%, and 44.7%, 
respectively;   P       =     .04 (FEC50 vs epirubicin alone) and   P       =     .006 
(FEC75 vs epirubicin alone). However, compared with epirubicin 
alone, use of these combinations did not prolong progression-free 
interval or OS (  17  ). Comparable results have also been reported in 
a study in Finland (  18  ) with a similar design and in a study in 
Germany (  19  ) using single-agent mitoxantrone as the reference 
regimen. The study in Finland (  18  ) was one of the few studies to 
  Table 1    .       Factors to consider when choosing between sequential and combination chemotherapy   
    Patient related Disease related   
    Menopausal status Endocrine responsiveness 
  Biological age and comorbidities (including organ dysfunction) HER2 status 
  Performance status and adverse effects       of prior therapy Disease-free interval 
  Socioeconomic and psychological factors Previous therapies and response obtained 
  Patient preference Tumor burden (defined as number and site of metastases) 
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clearly compare a sequential single-agent strategy with a combina-
tion approach throughout the course of illness. Patients who were 
randomly assigned to receive single-agent epirubicin as first-line 
therapy were subsequently treated with single-agent mitomycin C 
(MMC) following progression. Patients who were randomly 
assigned to receive first-line FEC received combination MMC  –
  vinblastine following progression. This study (  18  ) was also one of 
the few trials to formally examine differences in QoL between 
patients who were treated with combination vs single-agent ther-
apy. It confirmed that combination therapy improves disease 
response with no improvement in progression-free interval or OS, 
at the expense of increased treatment-related toxicity and poorer 
self-assessed QoL (  18  ). 
  More recently, the taxanes have been shown to have compara-
ble antitumor activity to anthracyclines in MBC patients who have 
not received previous chemotherapy (  20  ). This observation has led 
to many trials investigating combinations of anthracyclines and 
taxanes. It should be recognized that anthracyclines and taxanes 
have overlapping toxicity proﬁ  les, because both classes of agents 
are known to be potent myelosuppressors. The Eastern Cooperative 
Oncology Group       1193 study randomly assigned 739 patients with 
untreated MBC to either doxorubicin (A) or paclitaxel (P) alone or 
to a combination of doxorubicin and paclitaxel (AP) (  21  ). RRs and 
time to treatment failure (TTF) were increased with combination 
therapy (RR for A, P, and AP was 36%, 34%, and 47%, respec-
tively;   P       =     .84 [A vs P],   P       =     .007 [A vs AP], and   P       =     .004 [P vs AP] 
and median TTF for       A vs P vs AP was    =    5.8 vs 6.0 vs 8.0 months, 
respectively;   P       =     .68 [A vs P],   P       =     .003 [A vs AP], and   P       =     .009 [P 
vs AP]). However, there was no improvement in median OS (A vs 
P vs AP, 18.9 vs 22.2 vs 22.0 months;   P       =     .60 [A vs P],   P       =     .82 [A 
vs AP], and   P       =     .49 [P vs AP]) or QoL (change in FACT-B baseline 
to 16 weeks; A vs P vs AP,     1.7 vs     2.8 vs     3.0;   P       =     not statisti-
cally signiﬁ   cant) with combination therapy. In a similar study, 
Conte et al. (  22  ) compared a preplanned schedule of four cycles of 
single-agent epirubicin followed by four cycles of single-agent 
paclitaxel with eight cycles of the combination regimen and found 
no statistically signiﬁ  cant difference in RR, progression-free inter-
val, or OS between the two approaches. Both of these studies 
(  21  ,  22  ) used a 3-weekly paclitaxel administration schedule, which 
was subsequently shown to be inferior to weekly paclitaxel or 
3-weekly docetaxel (  23    –    26  ). In a smaller study conducted by the 
Spanish Breast Cancer Research Group (GEICAM 9903) (  27  ), 144 
MBC patients were randomly assigned to three cycles of single-
agent doxorubicin followed by three cycles of single-agent doc-
etaxel, given on a 3-weekly schedule, or to six cycles of the 
doxorubicin  –  docetaxel combination (  27  ). Again, no differences in 
RR, progression-free interval, or OS were observed between the 
two groups, but more febrile neutropenia, asthenia, and diarrhea 
were reported in the combination arm. Likewise, a randomized 
phase II study of two different doxorubicin  –  docetaxel combination 
regimens failed to show a beneﬁ  t in RR, progression-free interval, 
OS, or toxicity when compared with docetaxel followed by doxo-
rubicin in the sequential monotherapy group (  28  ). 
  Other trials comparing single-agent anthracyclines with 
anthracycline-based regimens with either vinca alkaloids (  29    –    34  ), 
platinum analogs (  32  ,  35  ), MMC (  36  ), or etoposide (  37  ) have also 
failed to show a survival benefit in favor of the combination 
approach, but the majority of these studies were underpowered to 
detect small differences in survival.   
    Taxane Monotherapy vs Combination Regimens 
  A variety of studies have examined taxane monotherapy against 
combination regimens. Older studies compared single-agent tax-
anes with combination regimens, including agents with limited 
clinical activity no longer widely used in the management of MBC 
(    Supplementary     Table     3    , available online). For example, Nabholtz 
et al. (  38  ) compared docetaxel with the combination of MMC and 
vinblastine in a population of patients who had been previously 
treated with anthracyclines. In this trial, docetaxel monotherapy 
was associated with better RR, progression-free interval, and OS. 
Similarly in another trial, single-agent treatment with docetaxel 
improved RR and time to progression (TTP)       when compared with 
methotrexate and 5-FU, but not OS, with less toxicity (  39  ). 
Bonneterre et al. (  40  ) showed that docetaxel has similar antitumor 
efficacy as the combination of 5-FU and vinorelbine with a more 
favorable toxicity profile. In a study in Australia, 3-weekly pacli-
taxel monotherapy was associated with a similar RR, TTF, and 
QoL when compared with cyclophosphamide-methotrexate-5-
FU-prednisone, with a trend toward an improved OS that did not 
reach statistical significance (  41  ). These studies contributed to the 
establishment of taxane monotherapy as the standard second-line 
treatment following anthracyclines in MBC. 
  More recently, several studies have investigated the value of 
adding newer agents to a taxane backbone (    Supplementary     Table   
  4    , available online). O’Shaughnessy et al. (  12  ) randomly assigned 
511 MBC patients who were previously treated with anthracyclines 
to either 3-weekly docetaxel singly or in combination with capecit-
abine (XT) (  12  ). The XT combination was associated with an 
improved RR, TTP, and a 3-month prolongation in median OS 
(XT vs docetaxel alone: 14.5 vs 11.5 months, HR for death     =     0.775, 
  P       =     .013). No statistically signiﬁ   cant difference in QoL was 
observed between the two groups. However, grade 3  –  4 toxicity was 
more frequent in the group treated with combination therapy 
(71% vs 49%), primarily due to increases in diarrhea, stomatitis, 
and hand-foot syndrome. In the  XT group, 65% of patients 
required dose reduction during the course of treatment. An 
unplanned subset analysis of patients who underwent dose reduc-
tion to 950 mg/m  2   capecitabine and 55 mg/m 
2   docetaxel showed no 
statistically signiﬁ  cant difference in outcome when compared with 
patients who tolerated full XT dosing for the ﬁ  rst four cycles (  42  ). 
In this study, therapy in the event of progression was not prespeci-
ﬁ  ed. Fewer patients in the group that received docetaxel mono-
therapy received further chemotherapy on progression compared 
with the group that received combination therapy (63% vs 70%) 
and only 17% went on to receive capecitabine (  12  ). 
  Subsequent studies have tried to address the relative beneﬁ  ts of 
sequential monotherapy and combination therapy with docetaxel 
and capecitabine. In a relatively small randomized phase II trial 
(  43  ), 100 patients with previously treated MBC were randomly 
assigned to docetaxel monotherapy with single-agent capecitabine 
in the event of progression or the XT combination. Of patients 
who were initially treated with docetaxel monotherapy, 74% 
received capecitabine upon progression. A statistically signiﬁ  cant 
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TTP, and OS (22.0 vs 19.0 months,   P       =     .006) was observed. Similar 
to what was observed by O’Shaughnessy et al., more grade 3  –  4 
diarrhea, stomatitis, and hand  –  foot syndrome were seen in the 
combination therapy group and 52% of patients required dose 
reduction. In a larger trial in Mexico (  44  ), 368 MBC patients who 
had been treated with anthracycline were randomly assigned to 
upfront capecitabine monotherapy followed by a taxane on pro-
gression vs a combination of either capecitabine  –  paclitaxel (XP) or 
XT. In the capecitabine monotherapy arm, 64% of patients 
received taxane monotherapy on progression. Although higher 
RRs were observed in the combination therapy groups, no statisti-
cally signiﬁ   cant improvements in TTP or OS were observed. 
Fewer patients reported grade 3  –  4 toxicity with the combination 
of XT or XP compared with previous studies. 
  Gemcitabine has also demonstrated activity in MBC patients 
previously treated with multiple chemotherapies, with an RR of up 
to 37% (  45  ). Albain et al. (  10  ) randomly assigned 529 women 
whose MBC had been treated with anthracyclines to the combina-
tion of 3-weekly paclitaxel  –  gemcitabine (GP) vs paclitaxel mono-
therapy. In this study, RR, TTP, and OS were improved by the 
addition of gemcitabine to paclitaxel to an extent similar to that 
obtained with the XT regimen in the study by O’Shaughnessy 
et al. Compared with XT, fewer patients reported grade 3  –  4 toxic-
ity with the GP regimen, although more febrile neutropenia, 
thrombocytopenia, and fatigue were observed in the GP therapy 
group than in the paclitaxel monotherapy group. Patients who were 
treated with GP rated their QoL better than did patients who were 
treated with paclitaxel monotherapy. However, further therapy fol-
lowing progression in the paclitaxel monotherapy group was not 
prespeciﬁ  ed. Overall, the delivery of additional chemotherapy fol-
lowing progression was similar between the two groups, but only 
15.6% of patients in the paclitaxel monotherapy group crossed over 
to gemcitabine (  10  ). No data comparing GP with paclitaxel fol-
lowed by gemcitabine (P  →  G) are available. In a smaller study (  47  ), 
100 patients with MBC were randomly assigned to eight cycles of 
combination of gemcitabine and docetaxel (GT) or four sequential 
cycles of docetaxel followed by four cycles of gemcitabine (T  →  G). 
No difference in RR, TTP, and OS was observed       (  47  ).   
    Capecitabine Alone vs Combination Therapy 
  Single-agent capecitabine has impressive antitumor activity, with 
an RR up to 58% as first-line therapy for MBC (  44  ). A large study 
in Australia (  48  ) demonstrated that first-line capecitabine had a 
similar activity to CMF, with a favorable toxicity profile 
(    Supplementary     Table     5    , available online). Capecitabine pro-
longed the median OS (22 vs 18 months,   P       =     .02) in this head-to-
head comparison. These results are similar to those of a previous 
and smaller randomized phase II trial in the United States with a 
similar design (  49  ). Capecitabine is an oral agent with a favorable 
toxicity profile and thus an ideal control for evaluating combina-
tions with novel agents. In a recent phase III study (  50  ), 752 
women with anthracycline- and taxane-pretreated MBC were ran-
domly assigned to the combination of ixabepilone and capecitabine 
or capecitabine alone. Crossover to ixabepilone upon progression 
in the capecitabine monotherapy group was not mandated in the 
study protocol. The addition of ixabepilone improved RR (35% vs 
14%,   P   < .001) and prolonged median progression-free interval 
(5.8 vs 4.2 months,   P   < .001). Substantial increases in severe 
peripheral neuropathy, fatigue, and neutropenia were observed in 
the combination therapy group. Sufficient survival data were not 
available at the time of the initial publication. These data have led 
to the Food and Drug Administration approval of the combination 
of ixabepilone and capecitabine in anthracycline- and taxane-
pretreated MBC (  51  ).   
    Vinorelbine Alone vs Combination Therapy 
  Vinorelbine is a third-generation vinca alkaloid that improves       TTF 
and OS, without compromising QoL, when compared with mel-
phalan in anthracycline-pretreated MBC (  52  ). In the GEICAM 
9903 trial     (  53  ), 252 women with MBC pretreated with an anthracy-
cline and a taxane were randomly assigned to the combination of 
gemcitabine and vinorelbine (GV) vs vinorelbine alone 
(    Supplementary     Table     6    , available online). Although the addition of 
gemcitabine improved median progression-free interval (6.0 vs 4.0 
months,   P       =     .003), and there was a suggested improved RR in the 
GV group (36% vs 26%,   P       =     .093), there was no difference in OS 
between the two regimens. More patients who were treated with 
single-agent vinorelbine were offered further systemic therapy fol-
lowing progression, including 35% who received gemcitabine. QoL 
was not formally assessed in this study. Overall, both regimens were 
well tolerated, although there was slightly more toxicity with the 
combination regimen, including febrile neutropenia, alkaline phos-
phatase elevation, nausea, and vomiting. An older trial comparing 
single-agent vinorelbine vs 5-FU/leucovorin (LV) with the combi-
nation of mitoxantrone and 5-FU/LV (  54  ) did not show any differ-
ence in RR, TTP, or OS.   
    Single Agents No Longer Routinely Used vs Combination 
Therapy 
  Several studies compared single agents that are no longer routinely 
used in the management of MBC vs combination regimens. These 
trials are listed in     Supplementary     Table     7     (available online). Many 
of the studies were underpowered to show survival differences. 
The interpretation and relevance of these results is questionable 
now that modern agents with greater antitumor activity are used in 
the management of MBC.     
    Interpretive Summary 
  Although two meta-analyses have shown a slight improvement in 
OS with combination vs single-agent therapy in MBC (  15  ,  55  ), 
these overviews are heavily biased by the inclusion of clinical trials 
testing outdated chemotherapy regimens, many of which con-
tained serious methodological flaws, failed to mandate crossover in 
the single-agent arm, and did not measure the impact of therapy 
on patients’ QoL. Furthermore, it is possible that administration 
of additional lines of therapy upon progression may dilute the 
survival advantage of an upfront combination approach. 
Consequently, it is difficult to apply the conclusions of these meta-
analyses to current clinical practice when deciding whether a com-
bination or sequential approach should be used. 
  In the modern era, two well-conducted multi-institutional phase 
III clinical trials (  12  ,  10  ) have demonstrated that median OS is 
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using a taxane backbone in patients pretreated with anthracyclines. 
These two studies showed that RR and TTP were improved by 
combination therapy, at the expense of greater toxicity. 
Unfortunately, very few patients in the single-agent therapy groups 
of these studies crossed over to the additional drug used in the com-
bination regimen on progression. The failure to properly address 
the question of combination vs sequential monotherapy in these two 
studies limits the generalizability of the survival beneﬁ  t reported. 
  To date, only eight randomized studies have addressed this 
important clinical question (  Table 2  ). One large adequately pow-
ered study (  21  ) demonstrated similar efﬁ  cacy for upfront combina-
tion vs sequential anthracycline and taxane therapy, with greater 
toxicity in the combination arm. Similar results in terms of both 
efﬁ  cacy and toxicity were reported by ﬁ  ve other studies testing a 
variety of combination regimens (  22  ,  27  ,  28  ,  39  ,  44  ,  47  ). In a study in 
Scandinavia of patients who were previously treated with anthracy-
clines (  39  ), single-agent docetaxel demonstrated a higher RR and 
TTP than methotrexate-5-ﬂ   uorouracil therapy, although there 
was no difference in OS. Conversely, results from a small unpub-
lished study (  43  ) indicated that the combination of docetaxel and 
capecitabine improved RR, progression-free interval, and OS when 
compared with the sequential approach. The conclusions that can 
be drawn from these studies are limited by heterogeneity in trial 
design and conduct. The approach to sequential therapy varied 
greatly because many of the studies started treatment with a second 
agent following a predeﬁ  ned number of cycles of initial non  –  cross-
resistant monotherapy (  22  ,  27  ,  28  ,  47  ) rather than pursuing the 
standard clinical practice of using symptomatic and/or radiographic 
progression as the trigger for shifting to second-line therapy.         
  It appears that combination therapy is associated with an 
improved RR and TTP compared with sequential therapy with 
greater expected treatment-related toxicity ( Table 3 ). Unfortunately, 
it is difﬁ  cult to draw deﬁ  nitive conclusions regarding the impact of 
combination therapy on OS and QoL; the latter, in part, because 
many trials do not report the incidence of low-grade toxic effects 
that may be most relevant to patients with metastatic disease. 
Because MBC is an incurable disease and the main aim of treat-
ment is palliation, QoL and OS should be the ultimate endpoints 
against which any systemic therapy is evaluated. As a result, a prop-
erly conducted multi-institutional clinical trial with predeﬁ  ned 
therapy following progression in both the combination and 
sequential arms is needed. Prospective evaluation of treatment-
related side effects and the impact on QoL using standardized 
patient-reported questionnaires and/or interviews is strongly rec-
ommended. Moreover, urgent research is required on the develop-
ment and evaluation of supportive interventions that might 
  Table 2    .       Efficacy data from randomized studies with mandated crossover in the monotherapy arm  *     
    First author, 
      year (ref)
Comparison 
(No. of cycles 
if preplanned)
No. of 
patients
First-line 
therapy 
for MBC, 
%
      Response 
rate, %
Median TTF, 
mo (95% CI)
Median OS, 
mo (95% CI)
Patients who 
received 
crossover in 
monotherapy 
arm, %   
    Alba,    †     2004 (  27  ) A × 3   →   Doc × 3 144 100 61 (50 to 72) 10.5 (NR)   22.3  (NR) 81    ‡     
  A + Doc × 6     51 (39 to 63) 9.2 (NR)   21.8  (NR)  
  Beslija,  §   2006 (  43  ) Doc   →   X 100 100 40 (NR) 7.7 (NR)   19.0  (NR) 74 
  Doc + X     68 (NR)    ||   9.3  (NR)                          § 22.0  (NR)            ||            
  Conte,    †     2004 (  22  ) E × 4   →   Pac × 4 202 100 58 (NR) 10.8 (7.9 to 13.6)          ¶          26.0 (18.1 to 33.8) 65    ‡     
  E + Pac × 8     58 (NR) 11.0 (9.7 to 12.3)  ¶  20.0 (17.2 to 22.6)  
  Koroleva,    †     2001 (  28  ) Doc × 4   →   A × 4 193 100 56 (NR) 6.9 (4.9 to 8.5)    13.8 (9.0 to 24.9) NR 
  A + Doc  ¶   × 8     49 (NR) 6.7 (5.2 to 8.2)    11.9 (10.6 to 15.4)  
  A + Doc    †     × 8     59 (NR) 8.3 (7.1 to 9.2) 14.5 (9.6 to 24.2)  
  Sjöstrom,  §   1999 (  39  ) Doc   →   MF 238 85 42 (NR)    ||   6.3  (NR)      §     10.4  (NR) 50 
  MF   →   Doc     21 (NR) 3.0 (NR)   11.1  (NR)  
  Sledge,  §   2003 (  21  )A    →   Pac 739 85 36 (NR)       5.8 (NR)  # 18.9  (NR) 58 
  Pac   →   A     34 (NR) 6.0 (NR)  # 22.2  (NR) 59 
  A + Pac     47 (NR)        ||       8.0  (NR)            ||            ,  # 22.0  (NR)  
  Soto,  §   2006 (  44  )X    →   Pac or Doc 368 78 45 (NR) 8.4 (NR)  ¶ 31.5  (NR) 64 
  X + Pac     64 (NR)                        ||       6.7  (NR)  ¶ 33.1  (NR)  
  X + Doc     75 (NR)        ||       8.1  (NR)  ¶ 28.5  (NR)  
  Tomova,    †     2008 (  47  ) Doc × 4  →   G × 4 100 NR 28 (NR) 6.7 (4.7 to 9.0)  #  15.9 (11.3 to reached) 63 
  Doc + G × 8     31 (NR) 7.0 (5.5 to 8.2)  #  15.5 (13.7 to 19.8)    
    *     A    =    doxorubicin; A + Doc  †      =    doxorubicin 60 mg/m  2   and docetaxel 60 mg/m  2  ; A + Doc¶    =    doxorubicin 50 mg/m  2   and docetaxel 75 mg/m  2  ; CI    =    confidence interval; 
Doc    =    docetaxel; E    =    epirubicin; G    =    gemcitabine; MBC    =    metastatic breast cancer; MF    =    methotrexate-5-fluorouracil; NR    =    not reported; OS    =    overall survival; 
Pac    =    paclitaxel; TTF    =    time to treatment failure; X    =    capecitabine.   
      †       Trials with a preplanned number of monotherapy cycles before crossover.   
      ‡       Percentage of patients randomly assigned to sequential therapy who completed all planned cycles of chemotherapy.   
    §     Trials in which the monotherapy treatment group crossed over on progression.   
      ||       Statistically significant (  P     ≤   .05 using log-rank, Fisher exact, or      
2   two-sided test; combination is compared with the single-agent group).   
    ¶     Progression-free interval.   
    #     Time to disease progression.     jnci.oxfordjournals.org    JNCI | Commentary 1179
ameliorate the toxic effects and side effects associated with the 
otherwise most efﬁ  cacious chemotherapies. Consideration should 
also be given to well-deﬁ  ned translational research to better char-
acterize the molecular determinants of response to MBC therapy. 
Similar studies have been successfully performed in other cancer 
types (  56  ,  57  ). Such a prospective trial is under discussion within 
the Breast International Group and the Breast Cancer Intergroup 
of North America networks.         
  In the absence of such evidence to guide daily clinical deci-
sion making in MBC, both combination and sequential single-
agent chemotherapy are reasonable options as ﬁ  rst-line systemic 
therapy. An important question for future research is the clear 
deﬁ   nition of patients who may beneﬁ   t from a combination 
approach. Until such data are available, the ESO-MBC Task 
Force believes that sequential single-agent therapy should be 
the preferred choice for most MBC patients, in the absence of 
rapid clinical progression, life-threatening visceral metastases, 
or the need for rapid symptom and/or disease control. These 
recommendations reﬂ  ect consensus expert opinion and repre-
sent level 5 clinical evidence (  58  ). Ultimately, the choice 
between combination and sequential systemic therapy for MBC 
must involve an open discussion of potential side effects and 
logistical requirements with patients, taking into consideration 
the cost and availability of chemotherapeutic agents in local 
clinical practice settings.   
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